Contact:Juan Sanchez, M.D. Vice President Corporate Communications and Investor Relations of Intra-Cellular Therapies, Inc. Phone: 212-923-3344Burns McClellan, Inc.Lisa Burns Justin Jackson (Media)Email: firstname.lastname@example.orgPhone: 212-213-0006
NEW YORK, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq:ITCI) a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced two ITI-007 poster presentations at the 55th Annual Meeting of the American College of Neuropsychopharmacology being held in Hollywood, Florida, December 4-8, 2016. The poster presentation (Abstract M180), titled "Advancing the Clinical Development of Lumateperone (ITI-007) for the Treatment of Schizophrenia - Efficacy Data," will take place on Monday, December 5, 2016, 5:30 pm - 7:30 pm ET during Poster Session I. The poster presentation (Abstract M173), titled "Advancing the Clinical Development of Lumateperone (ITI-007) for the Treatment of Schizophrenia - Safety and Tolerability Data," will also take place on Monday, December 5, 2016, 5:30 pm - 7:30 pm ET during Poster Session I. About Intra-Cellular Therapies Intra-Cellular Therapies is developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases and diseases of the elderly, including Parkinson's and Alzheimer's disease. The Company is developing its lead drug candidate, ITI-007, for the treatment of schizophrenia, bipolar disorder, behavioral disturbances in patients with dementia, including Alzheimer's disease, depression and other neuropsychiatric and neurological disorders. ITI-007, a first-in-class molecule, is in Phase 3 clinical development for the treatment of schizophrenia, bipolar depression and agitation associated with dementia, including Alzheimer's disease. The Company is also utilizing its phosphodiesterase platform and other proprietary chemistry platforms to develop drugs for the treatment of CNS and other disorders.